SONIC HEALTHCARE LIMITED (SHL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SHL - SONIC HEALTHCARE LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

Sonic Healthcare is one of the world's largest medical diagnostics companies, providing laboratory and imaging services to medical practitioners, hospitals, community health services, and their collective patients. It was first listed in 1987.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$35.97

16 May
2022

-0.080

OPEN

$36.05

-0.22%

HIGH

$36.52

583,446

LOW

$35.91

TARGET
$39.397 9.5% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
EBO . SLA . CAJ . GXL . HSO . MPL . MVF . NHF . HLS . RHC . VRT . MDR . M7T . HLA . PSQ . SIL . PKS . ONT . DOC . BMT . NVL . AHX . ALC . ACL .
FNARENA'S MARKET CONSENSUS FORECASTS
SHL: 1
Title FY20
Actual
FY21
Actual
FY22
Forecast
FY23
Forecast
EPS (cps) xxx 275.5 311.5 xxx
DPS (cps) xxx 91.0 99.4 xxx
EPS Growth xxx 100.0% 13.1% xxx
DPS Growth xxx 7.1% 9.2% xxx
PE Ratio xxx N/A 11.4 xxx
Dividend Yield xxx N/A 2.8% xxx
Div Pay Ratio(%) xxx 33.0% 31.9% xxx

Dividend yield today if purchased 3 years ago: 3.44%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

2.55

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 08/03 - ex-div 40c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2022 FactSet UK Limited. All rights reserved
Title 201620172018201920202021
EPS Basic xxxxxxxxxxxxxxx275.5
DPS All xxxxxxxxxxxxxxx91.0
Sales/Revenue xxxxxxxxxxxxxxx9,127.8 M
Book Value Per Share xxxxxxxxxxxxxxx1,336.0
Net Operating Cash Flow xxxxxxxxxxxxxxx2,042.8 M
Net Profit Margin xxxxxxxxxxxxxxx14.41 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201620172018201920202021
Return on Capital Employed xxxxxxxxxxxxxxx21.99 %
Return on Invested Capital xxxxxxxxxxxxxxx14.14 %
Return on Assets xxxxxxxxxxxxxxx10.56 %
Return on Equity xxxxxxxxxxxxxxx21.99 %
Return on Total Capital xxxxxxxxxxxxxxx22.87 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx1,353.7 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.4

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

2

xxxxxxxxx xx xxxxxxxxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Credit Suisse

23/03/2022

1

Upgrade to Outperform from Neutral

$40.00

11.20%

With Sonic Healthcare's shares underperforming the ASX200 by -22% year-to-date, Credit Suisse believes the market is underestimating the opportunity that remains for the company in covid testing.

With the shift to rapid antigen tests, the broker believes PCR testing levels have stabilised at 80,000 per day and expects this will normalise to 50,000 tests per day, forecasting a $890m second half revenue benefit compared to the $1.3bn achieved in the first half.

Combined with pent-up demand driving strong base business performance, Credit Suisse increases earnings per share estimates 6% and 3% in FY22 and FY23 respectively.

The rating is upgraded to Outperform from Neutral and the target price of $40.00 is retained.

FORECAST
Credit Suisse forecasts a full year FY22 dividend of 97.75 cents and EPS of 302.00 cents.
Credit Suisse forecasts a full year FY23 dividend of 102.64 cents and EPS of 191.00 cents.

Morgans

xx/xx/xxxx

3

xxxxxxxxx xx xxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

SHL STOCK CHART